Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients - PubMed (original) (raw)
Case Reports
. 1998 Sep 1;92(5):1549-55.
Affiliations
- PMID: 9716582
Free article
Case Reports
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
C M Rooney et al. Blood. 1998.
Free article
Abstract
Epstein-Barr virus (EBV) causes potentially lethal immunoblastic lymphoma in up to 25% of children receiving bone marrow transplants from unrelated or HLA-mismatched donors. Because this complication appears to stem from a deficiency of EBV-specific cytotoxic T cells, we assessed the safety and efficacy of donor-derived polyclonal (CD4(+) and CD8(+)) T-cell lines as immunoprophylaxis and treatment for EBV-related lymphoma. Thirty-nine patients considered to be at high risk for EBV-induced lymphoma each received 2 to 4 intravenous infusions of donor-derived EBV-specific T lymphocytes, after they had received T-cell-depleted bone marrow from HLA-matched unrelated donors (n = 33) or mismatched family members (n = 6). The immunologic effects of this therapy were monitored during and after the infusions. Infused cells were identified by detection of the neo marker gene. EBV-specific T cells bearing the neo marker were identified in all but 1 of the patients. Serial analysis of DNA detected the marker gene for as long as 18 weeks in unmanipulated peripheral blood mononuclear cells and for as long as 38 months in regenerated lines of EBV-specific cytotoxic T cells. Six patients (15.5%) had greatly increased amounts of EBV-DNA on study entry (>2, 000 genome copies/10(6) mononuclear cells), indicating uncontrolled EBV replication, a complication that has had a high correlation with subsequent development of overt lymphoma. All of these patients showed 2 to 4 log decreases in viral DNA levels within 2 to 3 weeks after infusion and none developed lymphoma, confirming the antiviral activity of the donor-derived cells. There were no toxic effects that could be attributed to prophylactic T-cell therapy. Two additional patients who did not receive prophylaxis and developed overt immunoblastic lymphoma responded fully to T-cell infusion. Polyclonal donor-derived T-cell lines specific for EBV proteins can thus be used safely to prevent EBV-related immunoblastic lymphoma after allogeneic marrow transplantation and may also be effective in the treatment of established disease.
Copyright 1998 by The American Society of Hematology.
Similar articles
- Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P, Ringden O, Winiarski J, Ernberg I, Masucci MG. Gustafsson A, et al. Blood. 2000 Feb 1;95(3):807-14. Blood. 2000. PMID: 10648390 - Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Rooney CM, et al. Lancet. 1995 Jan 7;345(8941):9-13. doi: 10.1016/s0140-6736(95)91150-2. Lancet. 1995. PMID: 7799740 - Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
Sun Q, Burton R, Reddy V, Lucas KG. Sun Q, et al. Br J Haematol. 2002 Sep;118(3):799-808. doi: 10.1046/j.1365-2141.2002.03683.x. Br J Haematol. 2002. PMID: 12181048 Clinical Trial. - Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
Heslop HE, Rooney CM. Heslop HE, et al. Immunol Rev. 1997 Jun;157:217-22. doi: 10.1111/j.1600-065x.1997.tb00984.x. Immunol Rev. 1997. PMID: 9255632 Review. - Adoptive immunotherapy for Epstein-Barr virus-related lymphoma.
Smith CA, Ng CY, Loftin SK, Li C, Heslop HE, Brenner MK, Rooney CM. Smith CA, et al. Leuk Lymphoma. 1996 Oct;23(3-4):213-20. doi: 10.3109/10428199609054823. Leuk Lymphoma. 1996. PMID: 9031101 Review.
Cited by
- CAR T-cells for pediatric solid tumors: where to go from here?
Trautmann T, Yakobian N, Nguyen R. Trautmann T, et al. Cancer Metastasis Rev. 2024 Sep 24. doi: 10.1007/s10555-024-10214-6. Online ahead of print. Cancer Metastasis Rev. 2024. PMID: 39317919 Review. - Stem cell memory EBV-specific T cells control EBV tumor growth and persist in vivo.
Palianina D, Mietz J, Stühler C, Arnold B, Bantug G, Münz C, Chijioke O, Khanna N. Palianina D, et al. Sci Adv. 2024 Aug 23;10(34):eado2048. doi: 10.1126/sciadv.ado2048. Epub 2024 Aug 23. Sci Adv. 2024. PMID: 39178248 Free PMC article. - Cytokine Storm Syndromes Associated with Epstein-Barr Virus.
Verbist K, Nichols KE. Verbist K, et al. Adv Exp Med Biol. 2024;1448:227-248. doi: 10.1007/978-3-031-59815-9_16. Adv Exp Med Biol. 2024. PMID: 39117818 Review. - Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses.
Briercheck EL, Ravishankar S, Ahmed EH, Carías Alvarado CC, Barrios Menéndez JC, Silva O, Solórzano-Ortiz E, Siliézar Tala MM, Stevenson P, Xu Y, Wohns AW, Enriquez-Vera D, Barrionuevo C, Yu SC, Freud AG, Oakes C, Weigel C, Weinstock DM, Klimaszewski HL, Ngankeu A, Mutalima N, Samayoa-Reyes G, Newton R, Rochford R, Valvert F, Natkunam Y, Shustov A, Baiocchi RA, Warren EH. Briercheck EL, et al. Blood Adv. 2024 Jul 23;8(14):3731-3744. doi: 10.1182/bloodadvances.2023012461. Blood Adv. 2024. PMID: 38815238 Free PMC article. - Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation.
O'Reilly RJ, Prockop S, Oved JH. O'Reilly RJ, et al. Front Immunol. 2024 Jan 11;14:1290059. doi: 10.3389/fimmu.2023.1290059. eCollection 2023. Front Immunol. 2024. PMID: 38274824 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials